PharmaTher Holdings Ltd. (OTCQB: PHRRF; CSE: PHRM), the specialty pharmaceutical innovator focused on ketamine-based therapies, has announced FDA approval of its lead product, KETARx™, for anesthesia and sedation in surgical and diagnostic procedures. This milestone shifts PharmaTher decisively from development to commercial execution and marks the start of what leadership terms a “turning point” in the company’s history.

PharmaTher Holdings is preparing for the U.S. launch of KETARx™, its FDA-approved ketamine product for anesthesia and sedation. The approval makes KETARx™ the first ketamine product cleared by the FDA in an analgesic setting, addressing a market projected to grow from USD 725 million in 2024 to USD 3.4 billion by 2034.

Commercial Strategy & Execution

The acquisition builds on Terumo’s March 2025 investment via its corporate venture arm, Terumo Ventures. By integrating OrganOx’s advanced technology, Terumo aims to:

  • Broaden access to life-saving transplants,
  • Improve organ utilization, including from “marginal donors”
  • Reduce the burden on healthcare systems by minimizing emergency and nighttime procedures

Commercial Strategy & Execution

PharmaTher’s blended approach includes:

  • Immediate Launch Focus: Swift U.S. commercialization in high-access healthcare settings.
  • Global Expansion Prep: Plans are underway to initiate international regulatory filings to expand access globally.

Growing Pipeline & Future Indications

Advertisement

cGxPJobs Banner

Beyond its commercial agenda, PharmaTher is advancing clinical-stage programs targeting neurological and pain disorders:

  • Parkinson’s disease (levodopa-induced dyskinesia)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Complex Regional Pain Syndrome (CRPS)
  • A ketamine patch and wearable pump for mental health and pain conditions

These programs are positioned under the FDA’s 505(b)(2) pathway, leveraging the agency’s evolving openness to psychedelic-assisted therapies and real-world evidence. Chianelli underscored this as an exciting second phase in the company’s growth narrative

Market Opportunity & Significance

  • Ketamine Shortage Relief: Ketamine has been on the FDA’s drug shortage list since February 2018. The approval of KETARx™ offers a regulated, cGMP-compliant alternative to compounded versions.
  • Strategic Vision Fulfilled: KETARx™ is the first ketamine product approved in an analgesic context by the FDA—a triumph for PharmaTher’s focus and persistence.

Founded in April 2020 with a singular vision—“be all‑in on Ketamine”—PharmaTher has pursued the therapeutic promise of ketamine across anesthesia, pain, mental health, and neurological disorders. CEO Chianelli emphasizes that FDA approval validates their philosophy and positions the company for what he terms the “next chapter” of their journey toward delivering transformative care at scale.

Source: PharmaTher Press Release